Episodio 1: KRAS G12C: implicancias en CPCNP | Dr. Claudio Martin.
Episodio 2: Vida real: KRAS G12C como sub-grupo molecular | Dra. Lorena Lupinacci.
Episodio 3: KRAS G12C como biomarcador emergente
Con el apoyo de:
Referencias:
Torres R, Jorgensen N, Jankilevich G, Denamiel JP, Macadam P, Fernandez D, Spairani C, Lewi D et al; 2020. Situación actual del diagnóstico y tratamiento del cáncer de mama en Argentina. Informe ISALUD
AG2111011321
Referencias:
Referencias:
Loi et al. Proc Natl Acad Sci U S A. 2010; Zardavas et al. J Clin Oncol 2018; Saura et al, ESMO Congress 2017; Schmid et al, J Clin Oncol 2016; Mosele et al., ESMO Breast Cancer 2019. Abstr 1490; Mosele F, et al. AACR 2019. Abstract 4895; André F, et al. N Engl J Med. 2019;380:1929-194; Rugo HS, et al. AACR 2019. Abstract CT142; The Cancer Genome Atlas Network. Nature. 2012;490:61-70; Qin H, et al. PeerJ. 2018;6:e5092
AG2108205380
Referencias:
Torres-Guzman R et al. Oncotarget. 2017;8:69493-69507; Kim S et al. Oncotarget. 2018;9:35226-35240; Finn RS et al. Clin Cancer Res. 2020;26:110-121; Delach S. SABCS 2020. Poster PS19-10; Cejalvo JM et al., Cancer Res 77:2213-2221, 2017; Prat A, et al., JAMA Oncol 2:1287-1294, 2016; Turner et al., . J Clin Oncol 37:1169-1178, 2019; Finn RS et al., ClinCancer Res 26:110-121, 2019; Finn R et al., Cancer Res 78, 2018 (abstr P2-P09-10-P2-09-10). Prat A. et al., Cancer Res Treat 135:301-306, 201. Turner et al.,. J Clin Oncol 37:1169-1178, 2019. Prat A et al., J Clin Oncol. 2021 May 1;39(13):1458-1467; Martínez-Sáez O. ESMO Breast 2021. Poster 23P; Levin Tykjær Jørgensen C. Cancers. 2021;13:1592; Braso-Maristany F. ESMO Breast 2021. Poster 16P.
AG2108048392
Referencias:
Harbeck et al., De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. J Clin Oncol 39, 2021 (suppl 15; abstr 503)
Mayer et al., A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131. J Clin Oncol 39, 2021 (suppl 15; abstr 605).
Tutt et al., OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. J Clin Oncol 39, 2021 (suppl 15; abstr LBA1).
Slamon et al., Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). J Clin Oncol 39, 2021 (suppl 15; abstr 1001).
Cristofanilli et al., Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. J Clin Oncol 39, 2021 (suppl 15; abstr 1000).
Kalinsky et al.,Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 39, 2021 (suppl 15; abstr 1011).
AG2107150104
Referencias:
Robert C, et al. N Engl J Med. 2019;381(7):626-636. 2. Osgood C, et al. J Clin Oncol. 2019:37(suppl) [abstract 9508]. 3. Larkin J, et al. N Engl J Med. 2019;381 (16) :1535-1546. 4. Robert C, et al. Lancet Oncol. 2019;20 (9) :1239-1251. 5. Long GV, et al. Ann Oncol. 2017;28(7):1631-1639. 6. Robert C, et al. Presented at: European Cancer Congress; October 7-11, 2016; Copenhagen, Denmark [abstract LBA40]. Long GV et al. Lancet Oncol. 2016 Dec;17(12):1743-1754. doi: 10.1016/S1470-2045(16)30578-2. Epub 2016 Nov 16.
AG2109224452
Referencias:
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer, Vivek Subbiah et al., Journal of Clinical Oncology 2018 36:1, 7-13.
AG2109224449
Referencias:
1.Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice L Heinzerling, S Kühnapfel, D Meckbach, M Baiter, E Kaempgen, P Keikavoussi, G Schuler, A Agaimy, J Bauer, A Hartmann, F Kiesewetter & R Schneider-Stock British Journal of Cancer volume 108, pages2164–2171 (2013); 2. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod Pathol. 2018 Jan; 31(1): 24–38; 3. The role of BRAF V600 mutation in melanoma Paolo A Ascierto, John M Kirkwood, Jean-Jacques Grob, Ester Simeone, Antonio M Grimaldi, Michele Maio, Giuseppe Palmieri, Alessandro Testori, Francesco M Marincola, and Nicola Mozzillo, J Transl Med. 2012; 10: 85; 4. Current State of Target Treatment in BRAF Mutated Melanoma Enrica Teresa Tanda, Irene Vanni, Andrea Boutros, Virginia Andreotti, William Bruno, Paola Ghiorzo and Francesco Spagnolo Front. Mol. Biosci., 14 July 2020; 5. New Therapies for Advanced Thyroid Cancer Diprajan Laha, Naris Nilubol and Myriem Boufraqech. Front. Endocrinol., 22 May 2020; 6. Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res 2019;8(6):1119-1124
AG2109277141
Referencias:
1.Cortés-Funes, F., Bueno, J. P., Narváez, A., García-Valverde, A., & Guerrero-Gutiérrez, L. (2012). Funcionamiento familiar y adaptación psicológica en oncología. Psicooncología, 9(2/3), 335. Aríza, E. O., Cárdenas, M. B., Martínez, S., & Pinto, T. (2010). Afrontamiento ante el diagnóstico de cáncer. Revista de psicología GEPU, 1(2), 19-29; 2. Font, A., & Cardoso, A. (2009). Afrontamiento en cáncer de mama: pensamientos, conductas y reacciones emocionales. Psicooncología, 6(1), 27-42.
AG2111107366
Referencias:
Alpelisib prospecto ANMAT; André F, et al. N Engl J Med. 2019;380:1929-1940; André F, et al.
Ann Oncol. 2020;S0923-7534(20)43166-7; Rugo H, et al. Ann Oncol. 2020;31(8):1001-1010;
Juric D, et al. JAMA Oncol. 2018;e184475.; American Diabetes Association. Diabetes Care.
2017;41:S1-S135.; Lu Y-S, et al. ESMO 2020. Poster 301P; Wang DG, et al. Breast Cancer
Res Treat. 2020;183(1):227-237.
AG2112150936
Para mayor información de nuestros productos puede ingresar en: https://gskpro.com/es-ar/
Para solicitar información médica puede contactarse con nuestro servicio de información
médica a mila@gsk.com o al teléfono 0800-220-4752.
Para reportar eventos adversos o quejas de producto contacte a GSK a los teléfonos/e-mail:
0800-220-4752 bua-farmacovigilancia-rx@gsk.com
Este material está destinado para el uso exclusivo de los médicos / profesionales de la salud
GlaxoSmithKline S.A. - Carlos Casares 3690 B1644BCD, Victoria, Bs. As. | Tel 011 4725-8900
NP-AR-NRP-OGM-220002
